

JosÃ© Luis LÃ³pez-SendÃ³n

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2812416/publications.pdf>

Version: 2024-02-01

96
papers

15,011
citations

172207

29
h-index

39575

94
g-index

99
all docs

99
docs citations

99
times ranked

16025
citing authors

#	ARTICLE	IF	CITATIONS
1	Apixaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 981-992.	13.9	7,537
2	Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. <i>New England Journal of Medicine</i> , 2019, 381, 2497-2505.	13.9	1,696
3	Initial Invasive or Conservative Strategy for Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1395-1407.	13.9	1,508
4	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2016, 375, 1131-1141.	13.9	692
5	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2019, 380, 1326-1335.	13.9	687
6	Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2719-2728.	1.2	303
7	Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events. <i>European Heart Journal</i> , 2010, 31, 1449-1456.	1.0	185
8	Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2016, 67, 353-361.	1.2	173
9	Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. <i>European Heart Journal</i> , 2020, 41, 1720-1729.	1.0	154
10	Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y ₁₂ inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , 2016, 37, 1133-1142.	1.0	138
11	Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. <i>Lancet, The</i> , 2016, 387, 349-356.	6.3	109
12	Association of Sex With Severity of Coronary Artery Disease, Ischemia, and Symptom Burden in Patients With Moderate or Severe Ischemia. <i>JAMA Cardiology</i> , 2020, 5, 773.	3.0	101
13	Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2019, 4, 273.	3.0	100
14	Effect of P2Y ₁₂ Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 227.	3.8	89
15	Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up. <i>American Journal of Medicine</i> , 2015, 128, 766-775.	0.6	81
16	Bioabsorbable Intracoronary Matrix for Prevention of Ventricular Remodeling After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2016, 68, 715-723.	1.2	79
17	Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. <i>Circulation</i> , 2019, 139, 2292-2300.	1.6	78
18	Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction. <i>Circulation</i> , 2020, 142, 1725-1735.	1.6	77

#	ARTICLE	IF	CITATIONS
19	High-grade atrioventricular block in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events. <i>European Heart Journal</i> , 2015, 36, 976-983.	1.0	61
20	Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 489-496.	1.2	56
21	Natural History of Patients With Ischemia and No Obstructive Coronary Artery Disease. <i>Circulation</i> , 2021, 144, 1008-1023.	1.6	56
22	Anti-anginal drugs—beliefs and evidence: systematic review covering 50 years of medical treatment. <i>European Heart Journal</i> , 2019, 40, 190-194.	1.0	49
23	Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial. <i>European Heart Journal</i> , 2017, 38, 2813-2822.	1.0	45
24	CT Angiography Followed by Invasive Angiography in Patients With Moderate or Severe Ischemia—Insights From the ISCHEMIA Trial. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1384-1393.	2.3	37
25	Medical treatment of stable angina: A tailored therapeutic approach. <i>International Journal of Cardiology</i> , 2016, 220, 445-453.	0.8	36
26	Earlobe Crease Shapes and Cardiovascular Events. <i>American Journal of Cardiology</i> , 2015, 116, 286-293.	0.7	34
27	Long-term neurological outcomes in out-of-hospital cardiac arrest patients treated with targeted-temperature management. <i>Resuscitation</i> , 2018, 133, 33-39.	1.3	33
28	Influence of the temperature on the moment of awakening in patients treated with therapeutic hypothermia after cardiac arrest. <i>Resuscitation</i> , 2016, 103, 32-36.	1.3	31
29	Management of stable angina: A commentary on the European Society of Cardiology guidelines. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1401-1412.	0.8	30
30	Beta-blocker Use in ST-segment Elevation Myocardial Infarction in the Reperfusion Era (GRACE). <i>American Journal of Medicine</i> , 2014, 127, 503-511.	0.6	28
31	Arterial thrombotic complications in hospitalized patients with COVID-19. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 769-771.	0.4	28
32	Unresolved issues in the management of chronic stable angina. <i>International Journal of Cardiology</i> , 2015, 201, 200-207.	0.8	27
33	Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	27
34	Recommendations on sub-speciality accreditation in cardiology: The Coordination Task Force on Sub-speciality Accreditation of the European Board for the Speciality of Cardiology. <i>European Heart Journal</i> , 2007, 28, 2163-2171.	1.0	26
35	Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis. <i>American Heart Journal</i> , 2017, 190, 135-139.	1.2	26
36	Baseline Predictors of Low-Density Lipoprotein Cholesterol and Systolic Blood Pressure Goal Attainment After 1 Year in the ISCHEMIA Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e006002.	0.9	26

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 200-206.	1.4	25
38	Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy. <i>Stroke</i> , 2021, 52, 2096-2105.	1.0	25
39	Cardiovascular risk factors during cancer treatment. Prevalence and prognostic relevance: insights from the CARDIOTOX registry. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 859-868.	0.8	25
40	Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHFâ€¦. <i>European Journal of Heart Failure</i> , 2019, 21, 322-333.	2.9	24
41	Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. <i>European Journal of Heart Failure</i> , 2016, 18, 672-683.	2.9	21
42	Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study. <i>European Journal of Preventive Cardiology</i> , 2022, 28, 1864-1872.	0.8	19
43	Long term clinical outcomes in survivors after out-of-hospital cardiac arrest. <i>European Journal of Internal Medicine</i> , 2020, 74, 49-54.	1.0	18
44	New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. <i>European Journal of Heart Failure</i> , 2017, 19, 718-727.	2.9	17
45	Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Longâ€¦Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2021, 10, e017008.	1.6	17
46	History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. <i>American Heart Journal</i> , 2016, 175, 175-183.	1.2	16
47	COVID-19 and simultaneous thrombosis of two coronary arteries. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 676-677.	0.4	16
48	Quality Markers in Cardiology. Main Markers to Measure Quality of Results (Outcomes) and Quality Measures Related to Better Results in Clinical Practice (Performance Metrics). <i>INCARDIO (Indicadores Tj ETQq0 0 0 rgBT /Overlock 10 Tj Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 976-995.e10.	0.4	15
49	Clinical Characteristics, Management, and Outcomes of Acute Coronary Syndrome in Patients With Right Bundle Branch Block on Presentation. <i>American Journal of Cardiology</i> , 2016, 117, 754-759.	0.7	15
50	Tbx5 variants disrupt Nav1.5 function differently in patients diagnosed with Brugada or Long QT Syndrome. <i>Cardiovascular Research</i> , 2022, 118, 1046-1060.	1.8	15
51	Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]). <i>American Journal of Cardiology</i> , 2021, 148, 146-150.	0.7	15
52	Impact of stable angina on health status and quality of life perception of currently treated patients. The BRIDGE 2 survey. <i>European Journal of Internal Medicine</i> , 2019, 70, 60-67.	1.0	14
53	Age and Gender influence on time of arrival for STEMI patients during Covid-19 pandemic. <i>American Journal of Emergency Medicine</i> , 2021, 42, 244-245.	0.7	14
54	Predictors of Left Main Coronary Artery Disease in the ISCHEMIA Trial. <i>Journal of the American College of Cardiology</i> , 2022, 79, 651-661.	1.2	14

#	ARTICLE	IF	CITATIONS
55	Contemporary registries on P2Y12 inhibitors in patients with acute coronary syndromes in Europe: overview and methodological considerations: Table 1. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 232-244.	1.4	13
56	Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE. <i>Archives of Medical Science</i> , 2022, 18, 285-292.	0.4	13
57	Previous and New Onset Atrial Fibrillation and Associated Outcomes in Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events). <i>American Journal of Cardiology</i> , 2018, 122, 944-951.	0.7	11
58	Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1466-1475.	1.2	10
59	Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management. <i>JAMA Cardiology</i> , 2021, 6, 1023.	3.0	10
60	Stable Angina: Perception of Needs, Quality of Life and Management of Patients (BRIDGE Study)â€™A Multinational European Physician Survey. <i>Angiology</i> , 2019, 70, 397-406.	0.8	9
61	Percutaneous Balloon Pericardiectomy as the Initial and Definitive Treatment for Malignant Pericardial Effusion. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 357-363.	0.4	8
62	Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events. <i>International Journal of Cardiology</i> , 2016, 218, 291-297.	0.8	8
63	Long-term Follow-up After Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 37-44.	0.4	8
64	Pharmacological reasons that may explain why randomized clinical trials have failed in acute heart failure syndromes. <i>International Journal of Cardiology</i> , 2017, 233, 1-11.	0.8	8
65	Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	8
66	Systolic Blood Pressure and Outcome in Patients Admitted With Acute Heart Failure: An Analysis of Individual Patient Data From 4 Randomized Clinical Trials. <i>Journal of the American Heart Association</i> , 2021, 10, e022288.	1.6	8
67	Ranolazine: a better understanding of its pathophysiology and patient profile to guide treatment of chronic stable angina. <i>Future Cardiology</i> , 2022, 18, 235-251.	0.5	8
68	Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003183.	1.6	7
69	Poor Anticoagulation Control in Atrial Fibrillation: How Much Longer?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 740-742.	0.4	6
70	Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention. <i>Pharmacoeconomics - Open</i> , 2020, 4, 485-497.	0.9	6
71	Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction â€™ findings from the LATITUDEâ€™TIMI 60 trial. <i>American Heart Journal</i> , 2022, 243, 147-157.	1.2	5
72	Challenges in Oral Lipid-lowering Therapy: Position Document of the Spanish Society of Cardiology. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 1083-1087.	0.4	4

#	ARTICLE	IF	CITATIONS
73	Prevalence of Neuroendocrine Tumors in Patients With Cyanotic Congenital Heart Disease. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 673-675.	0.4	4
74	Concomitant Rivaroxaban and Dronedron Administration in Patients With Nonvalvular Atrial Fibrillation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 121-122.	0.4	4
75	State of the art approach to managing angina and ischemia: tailoring treatment to the evidence. <i>European Journal of Internal Medicine</i> , 2021, 92, 40-47.	1.0	4
76	Clinical characteristics and outcomes of acute coronary syndrome patients with left anterior hemiblock. <i>Heart</i> , 2014, 100, 1456-1461.	1.2	3
77	Blood Pressure Drops During Hospitalization for Acute Heart Failure Treated With Serelaxin: A Patient-Level Analysis of 4 Randomized Controlled Trials. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121009199.	1.6	3
78	Heart failure years after cancer treatment. <i>Future Cardiology</i> , 2015, 11, 433-440.	0.5	2
79	Dataset regarding baseline and follow-up characteristics of out-of-hospital cardiac arrest patients focused on neurological outcomes. <i>Data in Brief</i> , 2018, 21, 1140-1144.	0.5	2
80	Precision and reproducibility of non-automatic measurement of the QRS complex in potential candidates for cardiac resynchronization therapy. <i>Journal of Electrocardiology</i> , 2019, 57, 90-94.	0.4	2
81	ISCHEMIA Trial: Key Questions and Answers. <i>European Cardiology Review</i> , 2021, 16, e34.	0.7	2
82	In-Hospital Outcomes Associated With Fibrinolytic and Thienopyridine Use in Patients With ST-Segment Elevation Acute Myocardial Infarction. <i>The Global Registry of Acute Coronary Events. Revista Espanola De Cardiologia (English Ed)</i> , 2009, 62, 501-509.	0.4	1
83	Cardiac Arrest Survivors Before They Reach Hospital. <i>Beyond Cardiopulmonary Resuscitation. Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 606-608.	0.4	1
84	Prognostic impact of decisions taken by the heart team in patients evaluated for transcatheter aortic valve implantation. <i>Revista Portuguesa De Cardiologia</i> , 2015, 34, 587-595.	0.2	1
85	Diagnostic Value of NT-proBNP for Early Identification of Chagas Cardiomyopathy in Non-endemic Areas. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 783-785.	0.4	1
86	ST-elevation Myocardial Infarction in Anomalous Origin of Right Coronary Artery From the Left Sinus of Valsalva and Interarterial Course. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 596-598.	0.4	1
87	Device to Narrow the Coronary Sinus in Refractory Angina. <i>Revista Espanola De Cardiologia (English)</i> Tj ETQq1 1 0.784314 rgBT /Overbo	0.4	1
88	72-Year-old woman with effort angina >3 <12 months after acute myocardial infarction. <i>European Heart Journal Supplements</i> , 2019, 21, C21-C23.	0.0	1
89	Una historia resumida. Impacto de los avances en cardiopatía isquémica. <i>Revista Espanola De Cardiologia Suplementos</i> , 2017, 17, 2-6.	0.2	1
90	Comparison of Noninvasive Cardiac Test Strategies for Newly Diagnosed Chagas Disease in a Non-Endemic Zone. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 1480-1486.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Gender differences in antithrombotic treatment in patients with atrial fibrillation from Spain versus the rest of Western Europe. GLORIA-AF Program. Medicina Clínica, 2021, , .	0.3	1
92	New Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Findings and Implications of the ROCKET Study. Response. Revista Espanola De Cardiologia (English Ed), 2013, 66, 758-759.	0.4	0
93	Interpretation of optical coherence tomography images. Lancet, The, 2014, 383, 1887-1888.	6.3	0
94	Diagnosis and management of pulmonary embolism in critical situations: A cardiac challenge. Revista Portuguesa De Cardiologia, 2015, 34, 703-704.	0.2	0
95	Remarks on the Position Paper on Cardio-Onco-Hematology and Remarks on the Review of Cardiac Imaging Modalities for the Detection of Cardiotoxicity. Response. Revista Espanola De Cardiologia (English Ed), 2017, 70, 1029-1030.	0.4	0
96	Different patterns of in-stent coverage in drug-eluting stents. Revista Portuguesa De Cardiologia, 2017, 36, 873-874.	0.2	0